La DL50 in caso di somministrazione per via intraperitoneale superiore a 3600 mg/kg e maggiore di 1600 mg/kg, quando la somministrazione sia per via endovenosa
Speak with your healthcare provider if any of these apply to you: History of pancreatitis Thyroid tumour history Severe kidney concerns Type 1 diabetes History of eating disorders Pregnant or breastfeeding Under 18 years of age Known peptide allergies The following events were uncommon in research and typically resolved without intervention: Gallstone formation: Infrequent, comparable to other GLP-1 class medications Dysesthesia (tingling/numbness): Mild and temporary in most cases, linked to glucagon receptor activity Injection site reactions: Minor redness or swelling at the injection site, resolving quickly Protect from light Avoid freeze-thaw cycling Refrigerate after reconstitution 20C Lyophilized Long-term 28C Reconstituted ~30 days Common questions about Retatrutide 50mg research and therapy Retatrutide 50mg is a synthetic peptide that simultaneously activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor
doi: 10.1007/s11695-023-06595-2
Post-discontinuation weight regain has been observed in trial extensions
Exendin-4 binds to and activates GLP-1 receptors found predominantly in pancreatic beta cells, the gastrointestinal tract, and the central nervous system
Still, it raises concerns about side effects, especially facial volume loss (Ozempic Face), which is now becoming a common topic in aesthetic medicine
